Ayala Pharmaceuticals, Inc. (AYLA) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 40 transactions totaling $24.7M, demonstrating a bullish sentiment with $22.6M in net insider flow. The most recent transaction on Jan 19, 2023 involved a transaction of 265,345 shares valued at $0.
No significant insider buying has been recorded for AYLA in the recent period.
No significant insider selling has been recorded for AYLA in the recent period.
Based on recent SEC filings, insider sentiment for AYLA is bullish with an Insider Alignment Score of 96/100 and a net flow of $22.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Ayala Pharmaceuticals, Inc. (AYLA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading AYLA stock, having executed 40 transactions in the past 90 days. The most active insider is 2. Fund Limited Partnership Amoon (Executive), who has made 3 transactions totaling $12.0M.
Get notified when executives and directors at AYLA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 19, 2023 | Mamluk Roni | Executive | Disposition | 265,345 | $N/A | $0 | |
| Jan 19, 2023 | Sidransky David | Executive | Disposition | 250 | $N/A | $0 | |
| Jan 19, 2023 | B. Gordon Gary | Executive | Disposition | 58,520 | $N/A | $0 | |
| Jan 19, 2023 | Maimon Yossi | Executive | Disposition | 69,872 | $N/A | $0 | |
| Jan 19, 2023 | Fund Limited Partnership Amoon Growth | Executive | Disposition | 2,991,473 | $N/A | $0 | |
| May 16, 2022 | Mamluk Roni | Executive | Award | 120,000 | $N/A | $0 | |
| May 16, 2022 | B. Gordon Gary | Executive | Award | 50,000 | $N/A | $0 | |
| May 16, 2022 | Maimon Yossi | Executive | Award | 50,000 | $N/A | $0 | |
| Feb 24, 2021 | Mamluk Roni | Executive | Sale | 10,800 | $17.40 | $187.9K | |
| Feb 24, 2021 | B. Gordon Gary | Executive | Option Exercise | 3,000 | $5.16 | $15.5K | |
| Feb 24, 2021 | B. Gordon Gary | Executive | Sale | 3,000 | $17.46 | $52.4K | |
| Feb 23, 2021 | Mamluk Roni | Executive | Sale | 7,126 | $17.89 | $127.5K | |
| Feb 22, 2021 | Mamluk Roni | Executive | Sale | 15,200 | $19.86 | $301.9K | |
| Jan 21, 2021 | Mamluk Roni | Executive | Sale | 1,406 | $15.04 | $21.1K | |
| Jan 20, 2021 | Mamluk Roni | Executive | Sale | 19,466 | $15.03 | $292.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 12 | $23.6M | 95.7% |
Sale(S) | 7 | $1.0M | 4.2% |
Exercise(M) | 2 | $31.0K | 0.1% |
Disposition(D) | 5 | $0 | 0.0% |
Award(A) | 8 | $0 | 0.0% |
Conversion(C) | 6 | $0 | 0.0% |
Insiders at Ayala Pharmaceuticals, Inc. are accumulating shares at an accelerated pace. With 8 insiders making 40 transactions totaling $23.6M in purchases versus $1.0M in sales, the net buying activity of $22.6M signals strong executive confidence. 2. Fund Limited Partnership Amoon (Executive) leads the buying activity with $12.0M in transactions across all time.